Mainz Biomed (MYNZ) announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The reverse stock split is expected to become effective on December 3, 2024, and the Company’s ordinary shares are expected to begin trading on the split-adjusted basis on the Nasdaq under the Company’s existing trading symbol “MYNZ” at market open on December 3, 2024, upon Nasdaq’s approval. The new CUSIP number for the Company’s ordinary shares following the reverse stock split will be N5436L119. The reverse stock split is intended to increase the market price per share of its common stock to comply with the continued listing standards of the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) and to make investments in the Company more attractive to investors by increasing the trading price of the Company’s ordinary shares on such market.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed downgraded to Neutral from Buy at H.C. Wainwright
- Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance
- Mainz Biomed Partners with Thermo Fisher for Cancer Screening
- Mainz Biomed, Thermo Fisher sign collaboration agreement
- Mainz Biomed files to sell 30.77M ordinary shares
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
